Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is a US-based clinical-stage pharmaceutical company that is breaking new ground in the medical field. Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm concentrates on the discovery, development, and commercialization of drugs for the treatment of cancer and other major diseases.
The company's pioneering research operates on the basis of nuclear transport - the intricate system of importing and exporting that happens within a body's cells. This transport system is essential for numerous cellular activities, including gene expression, cell signaling, and the maintenance of cell health. Karyopharm believes that the manipulation of these nuclear transport mechanisms can lead to the creation of new, better therapies for diseases that are currently difficult to treat, such as cancer, inflammation, and autoimmune diseases.
Karyopharm's novel drug candidate, Selinexor (XPO1), is a milestone in their research. It has been developed as an oral Selective Inhibitor of Nuclear Export (SINE) – a brand-new class of drugs. Selinexor works by binding to and inhibiting the nuclear export protein XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. This results in selective apoptosis (programmed cell death) of cancer cells while sparing healthy cells. It has shown promising efficacy in several forms of cancer, including hematologic malignancies and solid tumors.
In addition to Selinexor, Karyopharm has a promising pipeline of other drug candidates that are being tested for various malignant and non-malignant diseases. The company is also exploring partnerships with other pharmaceutical and biotech companies to expand applications for its novel SINE technology.
Karyopharm has attracted notable attention for its innovative approach, distinguished science, and strong clinical trial results. Despite global economic uncertainty, the company has managed to maintain a strong financial footing, attracting substantial investment from various stakeholders. In 2019, Selinexor received approval from the U.S. Food and Drug Administration for the treatment of relapsed or refractory multiple myeloma, marking a significant milestone for the company.
As of today, Karyopharm continues to push the boundaries of medical innovation, embodying its vision to eliminate the world's most daunting diseases and improve the lives of patients worldwide. Their commitment to drug discovery and development, coupled with their robust scientific approach,, guides them on their mission to deliver ground-breaking new treatments to patients who need them most.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends

This article lists 12 healthcare stocks that experienced significant movement during Monday's after-market session. Six companies saw their stock prices increase, including Karyopharm Therapeutics and Fractyl Health, while another six, such as Tvardi Therapeutics and Acadia Pharmaceuticals, experienced declines. The movements are attributed to various factors including recent earnings reports and market capitalization changes.
Latham & Watkins LLP advised the lenders to Karyopharm Therapeutics Inc. (Nasdaq: KPTI) on its Chapter 11 restructuring. Karyopharm has entered into a Restructuring Support Agreement with its lenders and noteholders, leading to a merger with Ayrmid Ltd. The company filed for Chapter 11 in the US Bankruptcy Court for the Southern District of Texas to implement the transaction, which is expected to close in the first quarter of 2027.
Karyopharm Therapeutics, maker of the multiple myeloma treatment Xpovio, has filed for Chapter 11 bankruptcy as part of a planned merger with Ayrmid, parent company of Gamida Cell. This restructuring agreement aims to convert approximately $276 million of funded debt into a majority stake in the combined company, with existing shares being canceled. The company will seek court approval for bidding procedures to allow competing offers, targeting a closing in the first quarter of 2027.

Karyopharm Therapeutics Inc., a biopharmaceutical company in Newton, Massachusetts, has filed for Chapter 11 bankruptcy protection as it plans to merge with Ayrmid Ltd. The company secured $55 million in debtor-in-possession financing to support ongoing operations during the restructuring. The process is intended to maximize value for stakeholders, with the merger expected to conclude by the first quarter of next year.
Karyopharm Therapeutics (Nasdaq: KPTI) has filed for Chapter 11 bankruptcy protection and entered a restructuring agreement with Ayrmid Ltd., which will serve as the lead bidder in a court-supervised sale process. This decision follows several clinical and regulatory setbacks, including missed endpoints in a myelofibrosis trial, rescinded FDA approval for XPOVIO in DLBCL, and a failed endometrial cancer trial. Karyopharm has secured up to $55 million in debtor-in-possession financing to continue operations through the bankruptcy process, with the transaction expected to close in Q1 2027.